Piper Jaffray Cos. reaffirmed their neutral rating on shares of Endo International PLC (NASDAQ:ENDP) in a report released on Tuesday. Piper Jaffray Cos. currently has a $19.00 price objective on the stock.
A number of other research firms have also weighed in on ENDP. Mizuho raised shares of Endo International PLC from a neutral rating to a buy rating and boosted their target price for the stock from $16.00 to $29.00 in a report on Friday, August 12th. Vetr lowered shares of Endo International PLC from a hold rating to a strong sell rating and set a $18.21 target price on the stock. in a report on Tuesday, August 9th. Citigroup Inc. reduced their target price on shares of Endo International PLC from $40.00 to $25.00 and set a buy rating on the stock in a report on Friday, September 16th. Morgan Stanley set a $16.00 target price on shares of Endo International PLC and gave the stock a hold rating in a report on Thursday, September 8th. Finally, Leerink Swann reissued a market perform rating and set a $22.00 target price on shares of Endo International PLC in a report on Friday, September 23rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. Endo International PLC presently has a consensus rating of Hold and an average target price of $37.50.
Shares of Endo International PLC (NASDAQ:ENDP) opened at 20.15 on Tuesday. The company’s 50 day moving average is $21.39 and its 200-day moving average is $21.13. The firm’s market capitalization is $4.49 billion. Endo International PLC has a one year low of $12.56 and a one year high of $72.85.
Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.12. The business earned $921 million during the quarter, compared to analysts’ expectations of $873.50 million. Endo International PLC had a negative net margin of 25.90% and a positive return on equity of 15.54%. The firm’s quarterly revenue was up 25.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.08 EPS. Equities analysts expect that Endo International PLC will post $4.56 EPS for the current year.
A number of institutional investors have recently bought and sold shares of ENDP. Heartland Advisors Inc. bought a new position in Endo International PLC during the second quarter valued at $15,627,000. State Street Corp raised its position in Endo International PLC by 9.3% in the second quarter. State Street Corp now owns 9,430,866 shares of the company’s stock valued at $147,021,000 after buying an additional 805,101 shares during the last quarter. Schneider Capital Management Corp bought a new position in Endo International PLC during the second quarter valued at $6,941,000. Quantitative Investment Management LLC raised its position in Endo International PLC by 166.2% in the second quarter. Quantitative Investment Management LLC now owns 654,800 shares of the company’s stock valued at $10,208,000 after buying an additional 408,800 shares during the last quarter. Finally, Alps Advisors Inc. bought a new position in Endo International PLC during the second quarter valued at $4,877,000. Institutional investors own 96.64% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.